→ Benoit C & Gorry P*, (2017), Health Technology Assessment: The Scientific Career of a Policy Concept, International J. Technology Assessment in Health Care, 33, 128-134.
→ Benoit C & Gorry P*, (2017), Health Technology Assessment: The Scientific Career of a Policy Concept, International J. Technology Assessment in Health Care, 33, 128-134.
→ Smith A., (2017), The Economic Driven by Politics as Values: The Example of Pharmaceuticals in France. New Political Economy. 22, 611-627.
→ Benoit C & Nogues E., (2018), De l’administration des prix à la régulation du marché : enjeux et modalités de la fixation des prix des médicaments en France depuis 1948., Revue Française des Affaires Sociales, 3, 91-109.
→ Gorry P* & Useche D., (2017), Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies. NBER working paper n° w24021.
→ Garden H., Paris V. & Gorry P. Pull Incentives for medical needs. OECD (eds), Science, Technology and Innovation Outlook 2016, Paris (France), OECD Publishing, 2016.
→ Gorry P* & Useche D. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies. in Ernst Berndt, Dana Goldman, and John Rowe (eds), Economic Dimensions of Personalized and Precision Medicine, University of Chicago Press, 2019.
Publishing, 2016.
→ Benoit C. Réguler l’accès aux médicaments, Presses Universitaires de Grenoble, 2020.
→ Faut-il de nouveaux modèles économiques ou financement pour accélérer le développement de nouveaux traitements des maladies rares (2014), Médecine/Sciences, 30 (HS n°1), 47-53.
→ Useche D, Gorry P, Orphan Drug Designations as valuable Intangible assets for IPO Investors in Pharma-Biotech Companies, DRUID Society Conf., Copenhague, June 13-15, 2016.
→ Gorry P, Serendipity and university technology transfer: a case study. XXVII Int. Soc. Prof. Innovation Management Conference, Porto, June 19-22, 2016
PDF
→ Gorry P, Useche D, Zumpe M, Empirical economic analysis of orphan drug legislation impact on innovation, Eur. Health Economic Association Conf., Hamburg, July 13-16, 2016.
→ Benoit C, Gorry P, How does regulation affect beliefs? The case of Stock Market Valuation of Orphan Drug Approval. Am. Political Sciences Asso. Conference, Philadelphia, Sept.1-4, 2016.
→ Gorry P, Pharma Competitive Intelligence using open source data and visualization tool: towards metrics for drug R&D milestones, 6th Global tech Mining Conf., Valencia, Sept. 13, 2016.
PDF
→ Gorry P, Useche D, Zumpe M, Empirical Economic Analysis of Orphan Drug Innovation, NBER Economic Dimensions of Personalized and Precision Medicine, Columbia Univ. NY, Sept 21-22, 2016.
→ Benoit C & Gorry P, Orphan Drugs: Why the US legislation approves more than the EU?, International Health Policy Conference, London School of Economics, Feb. 17-19, 2017.
PDF
→ Gorry P, Orphan Drug legislation: evaluation of the impact of market exclusivity extension, 12th International Health Economics Congress, Boston, July 8-11, 2017.
→ Benoit C, Gorry P, Useche D, Zumpe M, Empirical Economic Analysis of Orphan Drug Innovation, NBER Economic Dimensions of Personalized and Precision Medicine, Santa Monica. CA, Sept 13-14, 2017.
→ Gorry P, Lortal B & Breilh D. Evolution des prescriptions de médicaments orphelins en cancérologie : en France, et à l’échelle d’un établissement hospitalier. 30e Journées des Economistes de la Santé Français, Marseille, Nov. 30-Dec. 1, 2017.
PDF
→ Gorry P, Orphan Drug Market Exclusivity Extension versus Patent Monopoly. 7th Annual Conference of the American Society of Health Economists, Atlanta, June 10-13, 2018.
→ Gorry P. Does Orphan Drug market exclusivity incentive sustains drug development for rare diseases ? 12th European Conference on Health Economics, Maastricht, (NL), July11-14 , 2018.
PDF
→ Kourouklis D. & Gorry P, Market Valuation of FDA Orphan Drug Regulatory Events, 12th International Health Economics Congress, Basel, July 8-11, 2019.
→ Gorry P & Kourouklis D, R&D incentives and innovation spillovers: evidence from the European orphan drug regulation. 8th Biennial Atlanta Conf. on Science & Innovation Policy, Atlanta, Oct. 14-16, 2019.
→ Useche D & Gorry P, “Orphan Drug Designations as Valuable intangible assets for Ipo Investors in Pharma-biotech companies”, 65th Annual Meeting of the French Economic Association, Nancy, June 27-29, 2015.
→ Gorry P, Lortal B, Breilh D, Evolution des prescriptions de médicaments orphelins en cancérologie: en France et à l’échelle d’un établissement hospitalier. 12e Journée du Cancéropôle Grand Sud-Ouest, La Grande-Motte, Nov. 23-25, 2016.
→ Gorry P, & Bikfalvi A. Angiogenesis inhibitors drug pipeline landscape, 7ème Congrès de la Société Française d’Angiogénèse, Toulouse, April 23- 25, 2017.
→ Gorry P & Kouriklis D, Impact de la législation européenne des médicaments orphelins sur le marché global du médicament, RARE Rencontres des Maladies Rares, Paris, Nov. 4-5, 2019.
PDF
→ Gorry P & Useche D, Le statut de médicament orphelin est un signal positif pour les investisseurs lors de l’introduction en bourse des sociétés de biotechnologie, RARE Rencontres des Maladies Rares, Paris, Nov. 4-5, 2019.
PDF
→ Gorry P, Médicaments orphelins et maladies rares sur Twitter, RARE Rencontres des Maladies Rares, Paris, Nov. 4-5, 2019.
PDF
→ « Cancers rares & médicaments orphelins: quels médicaments innovants à quels prix ? » Séminaire CERMES, Paris, 18 Juin 2015.
→ « Economic analysis of the Orphan Drug market », Conférence Hospinnomics, AP-HP, Paris, 18 Nov., 2015.
→«Economic analysis of the Orphan Drug market », ELS seminar, OECD, Paris, Jan. 26, 2016.
→ « Impact économique de la dynamique du marché des médicaments orphelins : exemple des anticancéreux », Atelier Hospinnomics, AP-HP, Paris, 25 Janvier, 2016.
→ “Economic dimensions of Precision Medicine in Oncology”, Lake Como School of Advanced Studies on Cancer Development & Complexity, Como (IT), May 24-27, 2017.
→ « Analyse économique empirique de l’impact de la législation sur les médicaments orphelins en matière d’innovation », 5ème séminaire Innovation du LEDi « Jinnov » Univ.de Bourgogne, Dijon, 25 Juin 2018.
→ « Access to therapeutic innovations in Europe », Les journées Franco-Internationales d’Oncologie IFODS 2019, Paris, 13 juin 2019.
PDF
→ Table ronde, modérateur: Les réseaux de cancérologie, 12e Journées du Cancéropole, Grand Sud-Ouest, Montpellier, 23-25 Nov. 2016.
→ Table Ronde: « Le cancer, de la recherche à la prise en charge du patient », Roadshow Cancer Nouvelle-Aquitaine, 13 Dec. 2017.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.